Non-Neuron Brain Cells Produce a Third of Amyloid Plaque in Alzheimer's Disease - News CenterOligodendrocytes contribute to about one-third of amyloid plaque formation in Alzheimer's disease, challenging previous understanding and informing new therapies.
Lilly's Alzheimer's drug faces delayed reckoningFDA advisers are reviewing Eli Lilly's Alzheimer's drug application, impacting future treatments targeting amyloid plaques.
Non-Neuron Brain Cells Produce a Third of Amyloid Plaque in Alzheimer's Disease - News CenterOligodendrocytes contribute to about one-third of amyloid plaque formation in Alzheimer's disease, challenging previous understanding and informing new therapies.
Lilly's Alzheimer's drug faces delayed reckoningFDA advisers are reviewing Eli Lilly's Alzheimer's drug application, impacting future treatments targeting amyloid plaques.
FDA approves new Alzheimer's treatment, donanemab from Eli LillyThe FDA approved a new Alzheimer's treatment, donanemab, by Eli Lilly, aiming to slow brain decline in early-stage patients.